| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.07 | 0.2 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |